ArticleEndocrine oncology (Bristol, England)2026
Primary tumor size as a prognostic factor in duodenal neuroendocrine neoplasms ≤20 mm: a population-based SEER analysis.
Article in Endocrine oncology (Bristol, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Duodenal neuroendocrine neoplasms (NEN): update on endoscopic and surgical management].Chirurgie (Heidelberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The prognostic value of primary tumor size in duodenal neuroendocrine neoplasms (dNENs) ≤20 mm remains uncertain. Although size is used to guide management, its independent effect on survival is unclear. Design and methods: We performed a population-based study using the US SEER database (1975-2021), including adults with histologically confirmed dNENs ≤20 mm. Disease-specific survival (DSS) was the primary endpoint. Associations between tumor size, stage, lymph-node involvement, and DSS were evaluated using chi-squared tests, logistic regression, Kaplan-Meier curves, and Cox models. Receiver operating characteristic (ROC) analysis identified the optimal size cutoff. Mediation analysis assessed whether stage or grade mediated the size-DSS relationship. Results: Among 3,515 eligible cases, median age was 65 years, 51% were male, and 89% had well-differentiated NETs. Most tumors were localized (85.2%) and ≤10 mm (74.4%). Median follow-up was 56 months, with 160 disease-specific deaths (4.6%). In univariable analysis, size >10 mm was associated with worse DSS, but the association disappeared after adjustment for grade, stage, and surgery. Grade G3 and advanced stage independently predicted poorer survival, while radical surgery was protective. Larger tumors were more frequently high grade and advanced stage ( Conclusions: In duodenal NENs ≤ 20 mm, tumor size >10 mm correlates with disease extent but does not independently affect DSS, supporting its role as a stratification marker rather than a prognostic factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.